Major setback at Exelixis as Cometriq fails in prostate cancer
This article was originally published in Scrip
Executive Summary
Exelixis has suffered a major setback as its cancer drug Cometriq (cabozantinib) failed to demonstrate overall survival in the Phase III COMET-1 trial in men with metastatic castration-resistant prostate cancer (mCRPC). It has announced a 70% reduction in its workforce following the news.